首页 > 最新文献

Actualites Pharmaceutiques最新文献

英文 中文
Évaluez-vous ! Évaluez-vous !
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.016
{"title":"Évaluez-vous !","authors":"","doi":"10.1016/j.actpha.2024.07.016","DOIUrl":"10.1016/j.actpha.2024.07.016","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensibiliser et participer à la vaccination à l’officine 提高药房对疫苗接种的认识并参与其中
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.006
{"title":"Sensibiliser et participer à la vaccination à l’officine","authors":"","doi":"10.1016/j.actpha.2024.07.006","DOIUrl":"10.1016/j.actpha.2024.07.006","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Le daridorexant (Quviviq®) pour le traitement de l’insomnie chronique 用于治疗慢性失眠的 Daridorexant (Quviviq®)
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.002
Quviviq® est un nouveau médicament permettant de traiter les insomnies. Le daridorexant, son principe actif, est un antagoniste des récepteurs de l’orexine, agissant à la fois sur les récepteurs de l’orexine 1 et 2. Ce premier antagoniste double des récepteurs de l’orexine est une molécule au mécanisme d’action innovant ayant pour objectif d’inhiber les systèmes d’éveil.
Quviviq® is a new drug for treating insomnia. Its active ingredient, daridorexant, is an orexin receptor antagonist, acting on both orexin-1 and 2 receptors. This first dual orexin receptor antagonist is a molecule with an innovative mechanism of action designed to inhibit arousal systems.
Quviviq® 是一种治疗失眠症的新药。其活性成分 daridorexant 是一种奥曲肽受体拮抗剂,同时作用于奥曲肽-1 和奥曲肽-2 受体。Quviviq® 是一种治疗失眠症的新药。其活性成分 daridorexant 是一种奥曲肽受体拮抗剂,同时作用于奥曲肽-1 和奥曲肽-2 受体。这种首创的双重奥曲肽受体拮抗剂是一种具有创新作用机制的分子,旨在抑制唤醒系统。
{"title":"Le daridorexant (Quviviq®) pour le traitement de l’insomnie chronique","authors":"","doi":"10.1016/j.actpha.2024.07.002","DOIUrl":"10.1016/j.actpha.2024.07.002","url":null,"abstract":"<div><div>Quviviq® est un nouveau médicament permettant de traiter les insomnies. Le daridorexant, son principe actif, est un antagoniste des récepteurs de l’orexine, agissant à la fois sur les récepteurs de l’orexine 1 et 2. Ce premier antagoniste double des récepteurs de l’orexine est une molécule au mécanisme d’action innovant ayant pour objectif d’inhiber les systèmes d’éveil.</div></div><div><div>Quviviq® is a new drug for treating insomnia. Its active ingredient, daridorexant, is an orexin receptor antagonist, acting on both orexin-1 and 2 receptors. This first dual orexin receptor antagonist is a molecule with an innovative mechanism of action designed to inhibit arousal systems.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Savoir identifier les symptômes de l’endométriose, une priorité 了解如何识别子宫内膜异位症的症状是当务之急
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.001
{"title":"Savoir identifier les symptômes de l’endométriose, une priorité","authors":"","doi":"10.1016/j.actpha.2024.07.001","DOIUrl":"10.1016/j.actpha.2024.07.001","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prévention des infections à virus respiratoire syncytial 预防呼吸道合胞病毒感染
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.008
Le virus respiratoire syncytial est responsable d’infections des voies aériennes supérieures et inférieures potentiellement graves à tous les âges de la vie. Des comportements simples et efficaces axés sur le respect des règles d’hygiène limitent la transmission du virus qui est à l’origine, entre autres, de la bronchiolite. La mise à disposition et le développement de nouveaux traitements préventifs à base d’anticorps monoclonaux ou fondés sur la vaccination permettront d’assurer la protection de l’ensemble des populations fragiles.
The respiratory syncytial virus is responsible for potentially serious infections of the upper and lower airways at all ages. Simple, effective hygiene practices limit transmission of the virus that causes bronchiolitis, among other diseases. The availability and development of new preventive treatments based on monoclonal antibodies or vaccination will ensure the protection of all fragile populations.
呼吸道合胞病毒可导致所有年龄段的上呼吸道和下呼吸道发生潜在的严重感染。遵守卫生规则这一简单有效的行为限制了病毒的传播,而病毒是支气管炎和其他疾病的病因。呼吸道合胞病毒是所有年龄段人群上呼吸道和下呼吸道潜在严重感染的罪魁祸首。简单有效的卫生习惯可限制病毒的传播,而病毒是导致支气管炎等疾病的病因。以单克隆抗体或疫苗接种为基础的新型预防性疗法的出现和发展将确保所有脆弱人群得到保护。
{"title":"Prévention des infections à virus respiratoire syncytial","authors":"","doi":"10.1016/j.actpha.2024.07.008","DOIUrl":"10.1016/j.actpha.2024.07.008","url":null,"abstract":"<div><div>Le virus respiratoire syncytial est responsable d’infections des voies aériennes supérieures et inférieures potentiellement graves à tous les âges de la vie. Des comportements simples et efficaces axés sur le respect des règles d’hygiène limitent la transmission du virus qui est à l’origine, entre autres, de la bronchiolite. La mise à disposition et le développement de nouveaux traitements préventifs à base d’anticorps monoclonaux ou fondés sur la vaccination permettront d’assurer la protection de l’ensemble des populations fragiles.</div></div><div><div>The respiratory syncytial virus is responsible for potentially serious infections of the upper and lower airways at all ages. Simple, effective hygiene practices limit transmission of the virus that causes bronchiolitis, among other diseases. The availability and development of new preventive treatments based on monoclonal antibodies or vaccination will ensure the protection of all fragile populations.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
actualités santé publique 公共卫生新闻
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.09.018
{"title":"actualités santé publique","authors":"","doi":"10.1016/j.actpha.2024.09.018","DOIUrl":"10.1016/j.actpha.2024.09.018","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Produits 产品
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.09.020
{"title":"Produits","authors":"","doi":"10.1016/j.actpha.2024.09.020","DOIUrl":"10.1016/j.actpha.2024.09.020","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunosuppresseur et vaccin contre la varicelle et le zona 免疫抑制剂和预防水痘和带状疱疹的疫苗
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.004
L’administration d’une forte dose de méthylprednisolone dans le cadre d’une poussée de sclérose en plaques induit une immunosuppression qui contre-indique l’injection de vaccins vivants atténués tels que Zostavax® pendant trois mois. Le pharmacien doit systématiquement contrôler les antécédents des personnes souhaitant recevoir des vaccins vivants atténués à l’officine afin de vérifier l’absence de traitement immunosuppresseur antérieur.
The administration of a high dose of methylprednisolone in the context of a multiple sclerosis relapse induces immunosuppression, which contraindicates the injection of live attenuated vaccines such as Zostavax® for three months. Pharmacists should systematically check the medical history of people wishing to receive live attenuated vaccines at the pharmacy, to verify the absence of previous immunosuppressive treatment.
在多发性硬化症复发的情况下使用大剂量甲基强的松龙会引起免疫抑制,因此在三个月内禁忌注射减毒活疫苗,如 Zostavax®。在多发性硬化症复发的情况下使用大剂量甲基强的松龙会引起免疫抑制,因此在三个月内禁忌注射减毒活疫苗,如 Zostavax®。药剂师应系统地检查希望在药房接种减毒活疫苗者的病史,以核实之前是否接受过免疫抑制治疗。
{"title":"Immunosuppresseur et vaccin contre la varicelle et le zona","authors":"","doi":"10.1016/j.actpha.2024.07.004","DOIUrl":"10.1016/j.actpha.2024.07.004","url":null,"abstract":"<div><div>L’administration d’une forte dose de méthylprednisolone dans le cadre d’une poussée de sclérose en plaques induit une immunosuppression qui contre-indique l’injection de vaccins vivants atténués tels que Zostavax® pendant trois mois. Le pharmacien doit systématiquement contrôler les antécédents des personnes souhaitant recevoir des vaccins vivants atténués à l’officine afin de vérifier l’absence de traitement immunosuppresseur antérieur.</div></div><div><div>The administration of a high dose of methylprednisolone in the context of a multiple sclerosis relapse induces immunosuppression, which contraindicates the injection of live attenuated vaccines such as Zostavax® for three months. Pharmacists should systematically check the medical history of people wishing to receive live attenuated vaccines at the pharmacy, to verify the absence of previous immunosuppressive treatment.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vers une meilleure protection de la santé des patients contre les effets de la chaleur : résultats d’une enquête auprès des pharmaciens d’officine 更好地保护病人健康免受高温影响:配药药剂师调查结果
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.005
En complément des dispositifs de prévention et de gestion des risques sanitaires déployés par les institutions en cas de fortes chaleurs, le pharmacien d’officine doit se positionner comme un acteur de santé de premier recours afin de protéger mieux encore la santé de ses patients. Il peut adapter ses pratiques officinales et alerter spécifiquement les patients qui prennent un traitement à risque pouvant notamment aggraver une déshydratation ou altérer la thermorégulation de l’organisme. Il est aussi toujours utile de rappeler les bons gestes à adopter en cas d’épisode caniculaire et ce, plus particulièrement aux personnes vulnérables.
Towards a better protection of patients against health risks related to heat waves: Results from a survey of community pharmacists. In addition to national prevention and management systems for health risks related to heat waves, community pharmacists have a key role in primary health care to play in order to better protect patients’ health. Indeed, they can adapt pharmacy practices and specifically alert patients taking an at-risk treatment that could for instance worsen dehydration or alter thermoregulation. They should also remind people, and more particularly the most vulnerable ones, what to do in case of heat wave.
除了医疗机构在极端高温情况下实施的健康风险预防和管理措施外,配药师还必须将自己定位为初级医疗保健提供者,以便更有效地保护患者的健康。他们可以调整自己的药学实践,特别提醒正在接受可能会加重脱水或改变体温调节的高风险治疗的患者。更好地保护患者免受热浪带来的健康风险:社区药剂师调查的结果》(Towards a better protection of patients against health risks related to heat waves: Results from a survey of community pharmacists)。除了针对热浪相关健康风险的国家预防和管理系统外,社区药剂师在初级医疗保健中也可发挥关键作用,以更好地保护患者的健康。事实上,他们可以调整药房的做法,并特别提醒正在接受高风险治疗的患者,因为这种治疗可能会加重脱水或改变体温调节。他们还应该提醒人们,尤其是最脆弱的人群,在热浪来临时应该做些什么。
{"title":"Vers une meilleure protection de la santé des patients contre les effets de la chaleur : résultats d’une enquête auprès des pharmaciens d’officine","authors":"","doi":"10.1016/j.actpha.2024.07.005","DOIUrl":"10.1016/j.actpha.2024.07.005","url":null,"abstract":"<div><div>En complément des dispositifs de prévention et de gestion des risques sanitaires déployés par les institutions en cas de fortes chaleurs, le pharmacien d’officine doit se positionner comme un acteur de santé de premier recours afin de protéger mieux encore la santé de ses patients. Il peut adapter ses pratiques officinales et alerter spécifiquement les patients qui prennent un traitement à risque pouvant notamment aggraver une déshydratation ou altérer la thermorégulation de l’organisme. Il est aussi toujours utile de rappeler les bons gestes à adopter en cas d’épisode caniculaire et ce, plus particulièrement aux personnes vulnérables.</div></div><div><div>Towards a better protection of patients against health risks related to heat waves: Results from a survey of community pharmacists. In addition to national prevention and management systems for health risks related to heat waves, community pharmacists have a key role in primary health care to play in order to better protect patients’ health. Indeed, they can adapt pharmacy practices and specifically alert patients taking an at-risk treatment that could for instance worsen dehydration or alter thermoregulation. They should also remind people, and more particularly the most vulnerable ones, what to do in case of heat wave.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On vous demande, sachez répondre 我们在问你,所以要知道如何回答
IF 0.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-20 DOI: 10.1016/j.actpha.2024.07.003
{"title":"On vous demande, sachez répondre","authors":"","doi":"10.1016/j.actpha.2024.07.003","DOIUrl":"10.1016/j.actpha.2024.07.003","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":null,"pages":null},"PeriodicalIF":0.1,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Actualites Pharmaceutiques
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1